Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.52 |
| ▸ | BCL2L1 | Q07817 | 1/20 | 0.47 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
| ▸ | POLB | P06746 | 2/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
| ▸ | CNR2 | P34972 | 2/20 | 0.42 |
| ▸ | CA1 | P00915 | 1/20 | 0.41 |
| ▸ | CA2 | P00918 | 1/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | GSTO1 | P78417 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5503771 | 1.00 | KMT2A (0.52) | KMT2ABCL2L1MCL1ALDH1A1SMN1; SMN2 | |
| SCHEMBL5508316 | 0.89 | CNR2 (0.43) | KMT2AALDH1A1POLBTDP1L3MBTL1 | |
| SCHEMBL11409462 | 0.88 | KMT2A (0.46) | KMT2ABCL2L1MCL1ALDH1A1SMN1; SMN2 | |
| SCHEMBL11528664 | 0.86 | KMT2A (0.51) | KMT2ABCL2L1MCL1ALDH1A1SMN1; SMN2 | |
| SCHEMBL11349061 | 0.84 | ALDH1A1 (0.50) | KMT2AALDH1A1SMN1; SMN2TDP1L3MBTL1 | |
| SCHEMBL5508077 | 0.84 | ALDH1A1 (0.50) | KMT2AALDH1A1SMN1; SMN2TDP1L3MBTL1 | |
| SCHEMBL5504001 | 0.84 | ALDH1A1 (0.50) | KMT2AALDH1A1SMN1; SMN2TDP1L3MBTL1 | |
| SCHEMBL11346990 | 0.84 | ALDH1A1 (0.50) | KMT2AALDH1A1SMN1; SMN2TDP1L3MBTL1 | |
| SCHEMBL5508282 | 0.83 | ALDH1A1 (0.51) | KMT2AALDH1A1SMN1; SMN2TDP1L3MBTL1 | |
| SCHEMBL11346245 | 0.80 | CA1 (0.45) | ALDH1A1SMN1; SMN2POLBL3MBTL1CA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070265278-A1 | 2-PHENYL-INDOLES AS PROSTAGLANDIN D2 RECEPTOR ANTAGONISTS | AVENTIS PHARMACEUTICALS INC. (US) | 2007-11-15 | — | — | US | disclosed |
| EP-1844011-A1 | 2-PHENYL-INDOLES AS PROSTAGLANDIN D2 RECEPTOR ANTAGONISTS | Aventis Pharmaceuticals Inc. (US) | 2007-10-17 | — | — | EP | disclosed |
| WO-2006081343-A1 | 2-PHENYL-INDOLES AS PROSTAGLANDIN D2 RECEPTOR ANTAGONISTS | AVENTIS PHARMACEUTICALS INC. (US) | 2006-08-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070265278-A1 | 2-PHENYL-INDOLES AS PROSTAGLANDIN D2 RECEPTOR ANTAGONISTS | PTGDR2, PTGDR, CYSLTR2 | KMT2A 4133/4885BCL2L1 2190/4885MCL1 2714/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.